FGFR 1-4
Showing 26 - 50 of >10,000
MPN (Myeloproliferative Tumors) Trial in Worldwide (Pemigatinib)
Active, not recruiting
- MPN (Myeloproliferative Neoplasms)
-
Phoenix, Arizona
- +32 more
Jun 24, 2022
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York
Recruiting
- Advanced Solid Tumor
- +13 more
- [225Ac]-FPI-1966
- +2 more
-
Duarte, California
- +3 more
Oct 25, 2022
Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)
Recruiting
- Breast Cancer
- +3 more
- Infigratinib
- +3 more
-
Stanford, CaliforniaStanford University
Feb 16, 2022
Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid Tumors (MLN)
Active, not recruiting
- Advanced or Metastatic Solid Tumor
- +2 more
-
Gilbert, Arizona
- +60 more
Oct 20, 2022
Solid Tumor Trial in Tianjin (Pemigatinib)
Completed
- Solid Tumor
-
Tianjin, ChinaCancer Hospital of Tianjin Medical University
Jul 22, 2021
Urinary Bladder Tumors, Receptors, Fibroblast Growth Factor Trial in Japan (Erdafitinib Intravesical Delivery System)
Not yet recruiting
- Urinary Bladder Neoplasms
- Receptors, Fibroblast Growth Factor
- Erdafitinib Intravesical Delivery System
-
Kanagawa, Japan
- +3 more
Jan 27, 2023
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)
Not yet recruiting
- Advanced Solid Tumor
- +2 more
-
Palo Alto, California
- +9 more
Aug 2, 2022
Advanced and Metastatic Urothelial Cancer Trial in France, Spain, United States (futibatinib and pembrolizumab)
Recruiting
- Advanced and Metastatic Urothelial Cancer
- futibatinib and pembrolizumab
-
San Francisco, California
- +17 more
Oct 25, 2022
Facio-Scapulo-Humeral Dystrophy Trial (ARO-DUX4 for Injection, Placebo)
Not yet recruiting
- Facio-Scapulo-Humeral Dystrophy
- ARO-DUX4 for Injection
- Placebo
- (no location specified)
Nov 13, 2023
Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification Trial in Tianjin (Pemigatinib)
Recruiting
- Solid Tumor
- +4 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Second Hospital
Aug 28, 2023
Diabetes Trial in Nanjing (Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc)
Recruiting
- Diabetes
- Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
-
Nanjing, ChinaNanjing First Hospital, Nanjing Medical Univesity
Aug 6, 2023
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Worldwide (Bemarituzumab, Nivolumab, mFOLFOX6)
Recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Bemarituzumab
- +3 more
-
Phoenix, Arizona
- +119 more
Feb 1, 2023
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)
Not yet recruiting
- Locally Advanced Urothelial Carcinoma
- +3 more
- (no location specified)
Sep 15, 2022
Norovirus Infections, Norwalk Gastroenteritis Trial (Human Norovirus Bivalent (G?.1/G?.4)Vaccine,Recombinant (Hansenula
Not yet recruiting
- Norovirus Infections
- Norwalk Gastroenteritis
- Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)
- placebo
- (no location specified)
Jun 14, 2023
Urothelial Carcinoma Trial in Worldwide (Derazantinib dose level 1 (300mg once daily) monotherapy, Derazantinib various dose
Completed
- Urothelial Carcinoma
- Derazantinib dose level 1 (300mg once daily) monotherapy
- +4 more
-
Newnan, Georgia
- +65 more
Oct 19, 2022
Glioblastoma, Adult-type Diffuse Gliomas Trial in Worldwide (Pemigatinib)
Recruiting
- Glioblastoma
- Adult-type Diffuse Gliomas
-
Beverly Hills, California
- +83 more
Jul 25, 2022
Breast Cancer Trial in Ottawa, Toronto (Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab)
Not yet recruiting
- Breast Cancer
- Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab
-
Ottawa, Ontario, Canada
- +1 more
Jul 22, 2023
Symptomatic Irreversible Pulpitis Trial (3.6 ml 4% Articaine HCl, 1.8 ml 4% Articaine HCl)
Not yet recruiting
- Symptomatic Irreversible Pulpitis
- 3.6 ml 4% Articaine hydrochloride
- 1.8 ml 4% Articaine hydrochloride
- (no location specified)
Nov 3, 2023
Pediatric ALL Trial (4 hours of fasting time, 1 hour of fasting time)
Not yet recruiting
- Pediatric ALL
- 4 hours of fasting time
- 1 hour of fasting time
- (no location specified)
Mar 31, 2023
Malignant Tumor Trial in Ann Arbor, Columbus (ponatinib HCl, laboratory biomarker analysis)
Unknown status
- Malignant Neoplasm
- ponatinib hydrochloride
- laboratory biomarker analysis
-
Ann Arbor, Michigan
- +1 more
Feb 14, 2020